References
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702–11.
Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5: 199ra11.
Mascia F, Lam G, Keith C, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med 2013; 5: 199ra10.
Repertinger SK, Campagnaro E, Fuhrman J, El-Abaseri T, Yuspa SH, Hansen LA. EGFR enhances early healing after cutaneous incisional wounding. J Invest Dermatol 2004; 123: 982–9.
Campbell P, Morton PE, Takeichi T, et al. Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol 2014; 134: 2570–8.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Honda, Y., Hattori, Y., Katsura, S. et al. Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib. Eur J Dermatol 26, 413–414 (2016). https://doi.org/10.1684/ejd.2016.2807
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2016.2807